Illumina Presses $113.3M Bid For DNA Sequencer

Law360, New York (November 21, 2012, 2:30 PM EST) -- Illumina Inc., the gene-sequencing company that successfully fended off a hostile takeover earlier this year from pharmaceutical giant Roche AG, is now involved in a battle of its own after biotech firm Complete Genomics Inc. rejected its $113.3 million takeover offer Wednesday.

Illumina’s $3.30 per-share offer is about 5 percent higher than a rival bid from BGI-Shenzhen, the operator of Chinese DNA analysis centers that agreed to buy Complete Genomics in September. The would-be buyer said its takeover was more likely to close and have fewer...
To view the full article, register now.